Trinitrobenzenesulfonic Acid
"Trinitrobenzenesulfonic Acid" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A reagent that is used to neutralize peptide terminal amino groups.
| Descriptor ID |
D014302
|
| MeSH Number(s) |
D02.455.426.559.389.565.880.880 D02.640.529.880.900 D02.886.645.600.080.900
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Trinitrobenzenesulfonic Acid".
Below are MeSH descriptors whose meaning is more specific than "Trinitrobenzenesulfonic Acid".
This graph shows the total number of publications written about "Trinitrobenzenesulfonic Acid" by people in this website by year, and whether "Trinitrobenzenesulfonic Acid" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 0 | 2 |
| 1999 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 3 | 3 |
| 2008 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 1 | 1 | 2 |
| 2017 | 0 | 2 | 2 |
| 2018 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Trinitrobenzenesulfonic Acid" by people in Profiles.
-
Date AA, Halpert G, Babu T, Ortiz J, Kanvinde P, Dimitrion P, Narayan J, Zierden H, Betageri K, Musmanno O, Wiegand H, Huang X, Gumber S, Hanes J, Ensign LM. Mucus-penetrating budesonide nanosuspension enema for local treatment of inflammatory bowel disease. Biomaterials. 2018 12; 185:97-105.
-
Isidro RA, Lopez A, Cruz ML, Gonzalez Torres MI, Chompre G, Isidro AA, Appleyard CB. The Probiotic VSL#3 Modulates Colonic Macrophages, Inflammation, and Microflora in Acute Trinitrobenzene Sulfonic Acid Colitis. J Histochem Cytochem. 2017 08; 65(8):445-461.
-
Date AA, Rais R, Babu T, Ortiz J, Kanvinde P, Thomas AG, Zimmermann SC, Gadiano AJ, Halpert G, Slusher BS, Ensign LM. Local enema treatment to inhibit FOLH1/GCPII as a novel therapy for inflammatory bowel disease. J Control Release. 2017 Oct 10; 263:132-138.
-
Pag?n B, Isidro AA, Cruz ML, Ren Y, Coppola D, Wu J, Appleyard CB. Erlotinib inhibits progression to dysplasia in a colitis-associated colon cancer model. World J Gastroenterol. 2011 Nov 28; 17(44):4858-66.
-
Uronis JM, Arthur JC, Keku T, Fodor A, Carroll IM, Cruz ML, Appleyard CB, Jobin C. Gut microbial diversity is reduced by the probiotic VSL#3 and correlates with decreased TNBS-induced colitis. Inflamm Bowel Dis. 2011 Jan; 17(1):289-97.
-
Pag?n B, Isidro AA, Coppola D, Chen Z, Ren Y, Wu J, Appleyard CB. Effect of a neurokinin-1 receptor antagonist in a rat model of colitis-associated colon cancer. Anticancer Res. 2010 Sep; 30(9):3345-53.
-
Bulut K, Felderbauer P, Hoeck K, Schmidt WE, Hoffmann P. Increased duodenal expression of transforming growth factor-alpha and epidermal growth factor during experimental colitis in rats. Eur J Gastroenterol Hepatol. 2008 Oct; 20(10):989-94.
-
Santiago C, Pag?n B, Isidro AA, Appleyard CB. Prolonged chronic inflammation progresses to dysplasia in a novel rat model of colitis-associated colon cancer. Cancer Res. 2007 Nov 15; 67(22):10766-73.
-
Appleyard CB, Morales M, Santiago C. Chronic inflammation alters the contribution of neurokinin receptor subtypes to epithelial function in rat colon. Dig Dis Sci. 2008 Jan; 53(1):220-8.
-
Ogunwobi OO, Beales IL. The role of adiponectin in colitis. Gastroenterology. 2007 Mar; 132(3):1199-200; author reply 1200-1.